

Davy Strategic Global Equity Strategy

Quarterly Update Q1 2019

For Investment Professionals Only

Performance	1 Month (%)	Q1 2019 (%)	1 Year (%)	3 Year (P.A.) (%)	5 Year (P.A.) (%)
Davy Strategic Global Equity Strategy* (Net of Fees)	2.45	13.54	8.37	8.35	6.99

Source: Davy Asset Management (Class B Acc Eur) and Bloomberg as at 29th March 2019.

* Investment Management of the Davy Strategic Global Equity Fund was assumed by Davy Asset Management during the month of September 2018.

Fund Overview

The investment aim of the **Davy Strategic Global Equity Fund** (the 'Fund') is to provide long term capital growth spreading the risk through geographical and sector diversification whilst predominantly taking long only investment positions in mostly UK, European and U.S equity markets with some exposure to Japan, the Far East and emerging markets.

Fund Performance

The Fund rose 13.54% (net) during the first quarter of 2019 in euro terms. This compares with 13.57% for a 70/30 composite of MSCI ACWI/Euro STOXX and 14.51% for MSCI World. Toward the end of February, the Fund's positioning was brought closer in line with MSCI World Index following in-flows, by increasing exposure to North America which benefited performance in March.

Quality was one of the stronger performing styles for the quarter. Value stocks lagged as the markets were distinctly risk-on in the quarter. Growth stocks and smaller companies had a particularly strong start to the year.

Within MSCI World Index, the best performing sectors for the quarter were Information Technology and Real Estate, while Financials and Health Care lagged. Within Information Technology, initial rallies in the semiconductor names at the start of the year broadened out to the whole sector as the quarter progressed. Within Health Care, the larger value-oriented names lagged the sector, and there were some large idiosyncratic movements from the likes of Biogen which fell 30% after

the company ended the trial of the Alzheimer's drug, Aducanumab. Financials took a hit during March when the 3-month/10-year yield curve inverted.

North America was the best performing region over the quarter benefiting from the broad base rally in tech stocks. Whilst emerging markets posted strong gains in January, they failed to keep up with developed markets as the rally broadened out. European markets, which started well, fell off as the quarter progressed. Continued uncertainty around Brexit and Eurozone growth held the region back. Japan was the worst performing region for the quarter.

The first quarter of 2019 kicked off with a bang with a narrow rally in smaller growth stocks eventually widening out to the broader market. MSCI World Index finished March recovering its losses since October 2018. The index is back to trading on a P/E of 17.5 times which is up from 15.5 times at the start of the year and in-line with valuations seen in October 2018, however this is still below the 5Y average. Geopolitical stories continue to dominate the headlines, however, as we head into the second quarter. Brexit continues to be centre stage and will likely go down to the wire. The US/Chinese trade conflict looks to be improving which should boost market confidence on the other hand. The inversion of the yield curve in March could mean the markets will be looking to see if early warning signs of a recession manifest in other areas of the market – the Federal Reserve remains dovish.

Sample Portfolio Transactions

During the quarter the Fund started a position in the SPDR S&P 500 ETF.

Calendar Year Performance	2018 (%)	2017 (%)	2016 (%)	2015 (%)	2014 (%)
Davy Strategic Global Equity Fund (Net of Fees)	-8.60	8.12	7.43	7.58	12.89
MSCI World (Total Return, MSDEWIN)	-4.11	7.51	10.73	10.42	19.50
70/30 MSCI ACWI/Eurostoxx (Total Return Composite)	-7.2	10.0	9.0	9.2	14.3
USA (S&P 500, SPXT)	0.37	6.88	15.35	12.90	29.56
Europe (Euro Stoxx, SXXT)	-12.72	12.55	4.15	10.33	4.14
Asia Ex Japan (MSCI AC Asia Ex Japan, NDLECAJ)	-12.28	35.57	6.12	-5.59	7.40
UK (MSCI UK, NDDUUK)	-9.88	7.29	2.92	2.94	7.82
Ireland (ISEQ, ISEQTR)	-20.78	9.49	-2.68	33.61	16.83
Biogen Inc (USD)	-5.54	21.96	-7.43	-9.75	21.42

Source: Davy Asset Management (Class B Acc Eur) and Bloomberg as at 29th March 2019. Performance is quoted in EUR unless otherwise stated.

WARNING: Past performance is not a reliable guide to future performance.

WARNING: Neither past experience nor the current situation are necessarily accurate guides to the future growth in value or rate of return of the Fund. The value of the investment can reduce as well as increase and, therefore, the return on the investment will also be variable. Changes in exchange rates may have an adverse effect on the value price or income of the product.

This report does not constitute an offer for the purchase or sale of any financial instrument, trading strategy, product or service. No one receiving this report should treat any of its contents as constituting advice or a personal recommendation. It does not take into account the investment objectives or financial situation of any particular person. All investments involve a degree of risk. Equities may involve a high degree of risk and may not be suitable for all investors. Government bonds and cash deposits, although considered the safest assets, are not devoid of risk (e.g. inflation risk, credit risk, currency risk, etc.). There are different reasons why an investor would choose to invest in a particular asset class and each investor must consider the inherent risks therein based on his/her own personal circumstances. The value of these investments can rise as well as fall. There is no guarantee that the investments discussed will achieve results comparable to those achieved in the past or that capital will be returned to investors. Neither past experience nor the current situation are necessarily accurate guides to the future.

MSCI Inc. (MSCI). Without prior written permission of MSCI, this information and any other MSCI intellectual property may not be reproduced, disseminated or used to create any financial products, including any indices. This information is provided on an 'as is' basis. The user assumes the entire risk of any use made of this information. MSCI, its affiliates and any third party involved in, or related to, computing or compiling the information hereby expressly disclaim all warranties of originality, accuracy, completeness, merchantability or fitness for a particular purpose with respect to any of this information. Without limiting any of the foregoing, in no event shall MSCI, any of its affiliates or any third party involved in, or related to, computing or compiling the information have any liability for any damages of any kind. MSCI and the MSCI indexes are services marks of MSCI and its affiliates.

Davy Asset Management

Davy House, 49 Dawson Street, Dublin 2, D02 PY05, Ireland.
T +353 1 614 8874 E assetmanagement@davy.ie

www.davyassetmanagement.com

Confidential © Davy 2019

Davy Asset Management Limited, trading as Davy Asset Management, is regulated by the Central Bank of Ireland. In the UK, Davy Asset Management is authorised by the Central Bank of Ireland and authorised and subject to limited regulation by the Financial Conduct Authority. Details about the extent of our authorisation and regulation by the Financial Conduct Authority are available from us on request.

The Davy Strategic Global Equity Fund is a sub-fund of Davy Funds plc, an open-ended umbrella investment company with variable capital and segregated liability between sub-funds incorporated with limited liability under the Companies Acts 2014, authorised by the Central Bank of Ireland as a UCITS pursuant to the Regulations. Davy Funds plc is authorised by the Central Bank of Ireland as an Undertaking for Collective Investment in Transferrable Securities (UCITS). The Prospectus, Supplement and Key Investor Document for the fund are available in English from Davy Asset Management, Davy House, 49 Dawson Street, Dublin 2, Ireland or <http://www.davyassetmanagement.com/funds/davy-ucits/important-information.html>. Investors should be aware that some of the Directors of the Company (Davy Funds plc) are also employed by the Investment Manager, Promoter and Distributor. Further information in relation to the management of potential conflicts of interest is available upon request.

No part of this document is to be reproduced without our written permission. This document has been prepared and issued by Davy Asset Management on the basis of publicly available information, internally developed data and other sources believed to be reliable. The information contained herein does not purport to be comprehensive and is strictly for information purposes only. It does not constitute an offer or an invitation to invest. No party should treat any of the contents herein as advice in relation to any investment. While all reasonable care has been given to the preparation of this information, no warranties or representation expressed or implied are given or liability accepted by Davy Asset Management or its affiliates or any directors or employees in relation to the accuracy, fairness or completeness of the information contained herein. Any opinion expressed (including estimates and forecasts) may be subject to change without notice. We or any of our connected or affiliated companies or their employees may have a position in, or may have provided within the last twelve months, significant advice or investment services in relation to any of the securities or related investments referred to in this document.